September 2023 in “Journal of the American Academy of Dermatology” Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.
September 2023 in “Journal of the American Academy of Dermatology” This study evaluated the effect of guselkumab on moderate to severe plaque psoriasis and found that median PASI improvements increased from around 60% at week 4 to over 90% by week 12 of treatment across multiple clinical trials.
65 citations
,
January 2013 in “Cochrane library” This review found that infliximab, golimumab, and some forms of radiotherapy significantly improved nail psoriasis compared to controls, although they could have serious adverse effects and are not commonly used specifically for nail issues.
3 citations
,
March 2020 in “International Journal of Dermatology” This correspondence about the treatment of chronic alopecia areata with tildrakizumab reports no clinical results; the authors present an open-label pilot study setup.
3 citations
,
July 2022 in “European Journal of Dermatology” In this study, researchers using multistate modeling reported that patients with psoriasis treated with brodalumab had a higher probability of achieving and maintaining a therapeutic response compared to those treated with ustekinumab over 52 weeks, based on absolute PASI measurements.